Lay opinion vs evidence: Abnehmspritze Frauen

The term 'weight loss shot' commonly refers to GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda). Lay opinions often portray these as effortless weight loss solutions, but the evidence tells a more nuanced story. Large randomized controlled trials (e.g., STEP trials) show that semaglutide leads to an average weight loss of 15% body weight over 68 weeks when combined with lifestyle intervention. However, these drugs are approved for individuals with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. They are not intended for cosmetic weight loss. Side effects are common, including nausea, vomiting, diarrhea, and constipation, and some serious risks like pancreatitis and gallbladder disease exist. Moreover, weight regain is typical after discontinuation. The provided knowledge context does not directly address this topic; it focuses on DNA tests, hormone panels, and microbiome analysis. Therefore, while the evidence for GLP-1 agonists in appropriate populations is strong (human-strong from clinical trials), the context here is weak. Women considering these medications should consult a healthcare provider and understand that they are tools, not magic bullets.